Publication | Open Access

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

MedicinePathologyHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation OncologyPembrolizumab Versus Methotrexate